Literature DB >> 3033138

The two major structural phosphoproteins (pp65 and pp150) of human cytomegalovirus and their antigenic properties.

G Jahn, B C Scholl, B Traupe, B Fleckenstein.   

Abstract

Human cytomegalovirus (HCMV) purified from cell culture contains two dominant structural phosphoproteins with apparent molecular weights of 65,000 and 150,000, designated as pp65 and pp150 respectively. The humoral immune response of infected individuals against pp65 is relatively weak and is not always detectable by Western blot analyses. This report shows that recent clinical isolates of HCMV do not necessarily have pp65 as a prominent constituent, suggesting that the low immune reaction is due to variable expression of the pp65 in natural infections. However, the HCMV strains tested in this study produced the large structural phosphoprotein (pp150) in about equal amounts. The pp150 is remarkably immunogenic, if compared with all other virion constituents; serum pools and individual sera from HCMV-infected patients recognized this particular protein intensively in immunoblot assays. Thus, phosphoprotein pp150 seems to be the primary polypeptide candidate for expression cloning in order to develop reagents for novel ways of HCMV diagnosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3033138     DOI: 10.1099/0022-1317-68-5-1327

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  54 in total

1.  Cytomegalovirus basic phosphoprotein (pUL32) binds to capsids in vitro through its amino one-third.

Authors:  M K Baxter; W Gibson
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Viable human cytomegalovirus recombinant virus with an internal deletion of the IE2 86 gene affects late stages of viral replication.

Authors:  Veronica Sanchez; Charles L Clark; Judy Y Yen; Roopashree Dwarakanath; Deborah H Spector
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  The 85-kilodalton phosphoprotein (pp85) of human herpesvirus 7 is encoded by open reading frame U14 and localizes to a tegument substructure in virion particles.

Authors:  A Stefan; P Secchiero; T Baechi; W Kempf; G Campadelli-Fiume
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

4.  Detection of cytomegalovirus in urine samples by an enzyme-linked immunosorbent assay using a monoclonal antibody against the viral 150-kilodalton protein.

Authors:  T Yamanaka; K Kiyotani; T Sakaguchi; Y Fukuda; K Dohi; M Yamada; M Yoshida; S Nii; T Yoshida
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

5.  Large-scale screening of human sera with cytomegalovirus recombinant antigens.

Authors:  M P Landini; M X Guan; G Jahn; W Lindenmaier; M Mach; A Ripalti; A Necker; T Lazzarotto; B Plachter
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

6.  Human cytomegalovirus structural proteins: immune reaction against pp150 synthetic peptides.

Authors:  M P Landini; A Ripalti; K Sra; P Pouletty
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

7.  Characterization of human cytomegalovirus UL84 early gene and identification of its putative protein product.

Authors:  Y S He; L Xu; E S Huang
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

8.  Antibody response to recombinant lambda gt11 fusion proteins in cytomegalovirus infection.

Authors:  M P Landini; T Lazzarotto; A Ripalti; M X Guan; M La Placa
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

9.  Human antibody reactivity against the lower matrix protein (pp65) produced by cytomegalovirus.

Authors:  M Ohlin; B Plachter; V A Sundqvist; P G Steenbakkers; J M Middeldorp; C A Borrebaeck
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

10.  Inactivation of enveloped virus by laser-driven protein aggregation.

Authors:  Shaw-Wei D Tsen; Travis Chapa; Wandy Beatty; Kong-Thon Tsen; Dong Yu; Samuel Achilefu
Journal:  J Biomed Opt       Date:  2012-12       Impact factor: 3.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.